European Commission approves Orkambi for the treatment of children with cystic fibrosis ages 1 to less than 2 years old

“This approval will offer some of the youngest children with cystic fibrosis the chance of improved outcomes, by treating their disease at a young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “With this important milestone, we move ever closer to our goal of providing medicines that treat the underlying cause of CF to all people living with the disease.”

“CF symptoms and organ damage can manifest very early in life, so it is crucial to start treatment as early as possible,” said Silvia Gartner, M.D., specialist in Pediatrics and Pneumonology, Coordinator of the Pediatric Cystic Fibrosis Center, Barcelona. “Today’s approval provides us with a medicine that gives a window of opportunity to possibly delay the onset of CF for these very young eligible children.”

Orkambi has also been approved by regulatory authorities in the U.S., in Great Britain, Australia and Canada, for people with CF and two copies of the F508del mutation in the CFTR gene, ages 1 and above.

As a result of long-term reimbursement agreements in Austria, Denmark, the Republic of Ireland and Sweden, and provisions for access in health care systems such as Germany, eligible patients in these countries will have access to the expanded indication for Orkambi shortly following regulatory approval by the European Commission. As a result of the long-term reimbursement agreement in the UK, children ages 1 to less than 2 years old in the UK have had access to this expanded indication for Orkambi since MHRA approval in March 2023. Vertex will continue to work with reimbursement bodies across the European Union, Australia and Canada to ensure access for all eligible patients.